Compare · ABT vs LEXX
ABT vs LEXX
Side-by-side comparison of Abbott Laboratories (ABT) and Lexaria Bioscience Corp. (LEXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and LEXX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.99B, about 11500.5x LEXX ($13.4M).
- Over the past year, ABT is down 33.5% and LEXX is down 42.0% - ABT leads by 8.6 points.
- ABT has been more active in the news (9 items in the past 4 weeks vs 3 for LEXX).
- ABT has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Abbott Laboratories
- Lexaria Bioscience Corp.
- Price
- $88.42-0.03%
- $0.59-2.84%
- Market cap
- $153.99B
- $13.4M
- 1M return
- -0.48%
- +0.88%
- 1Y return
- -33.46%
- -42.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest LEXX
- GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
- Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
- Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
- Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
- Lexaria Bioscience Releases Second Episode of Investor Video Series
- Lexaria Updates Progress on Human Study #7
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales